AmbAgon Therapeutics develops targeted cancer molecule therapeutics that utilize specific molecular pathways to inhibit tumor growth. The company focuses on providing effective treatment options for patients with various types of cancer, addressing the need for more precise and less toxic therapies.
Funding
$103M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to toxic side effects and limited efficacy across diverse tumor types. There is a need for therapies that selectively target cancer cells while sparing healthy tissue, improving patient outcomes and quality of life.
Solution
AmbAgon Therapeutics develops targeted cancer therapeutics designed to selectively inhibit tumor growth by modulating specific molecular pathways. Their approach focuses on identifying and exploiting vulnerabilities within cancer cells to disrupt their proliferation and survival mechanisms. By targeting these pathways, AmbAgon aims to create more precise and less toxic therapies that can effectively treat various types of cancer. This targeted approach has the potential to minimize off-target effects and improve the therapeutic index of cancer treatments.
Target Audience
The primary target audience includes cancer patients, oncologists, and pharmaceutical companies seeking more effective and targeted cancer therapies.
Features
- Development of small molecule therapeutics that selectively bind to cancer-specific targets.
- Modulation of intracellular signaling pathways critical for tumor growth and survival.
- Preclinical validation of drug candidates in relevant cancer models.
- Focus on personalized medicine approaches to identify patients most likely to respond to treatment.